Chad Stutzman

Chad Stutzman is currently the Director of Strategic Partnerships at IDEOlogy Health. Previously, Chad worked at Incyte as an Oncology Therapeutic Specialist from July 2020 to March 2022, and at Genentech as a Senior Clinical Oncology Specialist-Immunotherapy from April 2006 to July 2020. Chad's portfolio at Genentech included Tecentriq, Avastin, and Tarceva. Chad holds a Bachelor of Science in Biomedical Science from Texas A&M University and a Master of Science in Pharmacy with a focus on Applied Pharmacoeconomics from the University of Florida.